Annovis Bio (ANVS) Accumulated Expenses (2019 - 2026)
Annovis Bio (ANVS) posted Accumulated Expenses of $734337.0 for Q1 2026, up 72.3% sequentially from $426202.0 in Q4 2025, and up 153.5% YoY from $289677.0 in Q1 2025.
Annovis Bio (ANVS) Accumulated Expenses (2019 - 2026) Analysis & Trends
Annovis Bio has reported Accumulated Expenses for 8 years, with the latest figure at $734337.0 in Q1 2026.
- Quarterly Accumulated Expenses rose 153.5% year-over-year to $734337.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $734337.0 (up 153.5% YoY) and the FY2025 annual result came in at $426202.0, up 16.86% from the prior year.
- Accumulated Expenses rose to $734337.0 in Q1 2026 per ANVS's latest filing, from $426202.0 in the prior quarter.
- Over five years, Accumulated Expenses peaked at $3.7 million in Q4 2022 and troughed at $260287.0 in Q2 2023.
- A 5-year average of $908959.3 and a median of $526890.0 in 2025 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2022 and 2024: Accumulated Expenses jumped 424.33% in 2022, then tumbled 87.79% in 2024.
- Over 5 years, Accumulated Expenses stood at $3.7 million in 2022, then decreased by 20.1% to $3.0 million in 2023, then sank by 87.79% to $364717.0 in 2024, then increased by 16.86% to $426202.0 in 2025, then surged by 72.3% to $734337.0 in 2026.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $734337.0, $426202.0, and $706650.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Annovis Bio | 67.91 Mn | 67.91 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 734,337.00 |
| Dec 31, 2025 | 426,202.00 |
| Sep 30, 2025 | 706,650.00 |
| Jun 30, 2025 | 526,890.00 |
| Mar 31, 2025 | 289,677.00 |
| Dec 31, 2024 | 364,717.00 |
| Sep 30, 2024 | 1.29 Mn |
| Jun 30, 2024 | 662,682.00 |
| Mar 31, 2024 | 264,113.00 |
| Dec 31, 2023 | 2.99 Mn |
| Sep 30, 2023 | 396,384.00 |
| Jun 30, 2023 | 260,287.00 |
| Mar 31, 2023 | 1.26 Mn |
| Dec 31, 2022 | 3.74 Mn |
| Sep 30, 2022 | 680,830.00 |
| Jun 30, 2022 | 397,544.00 |
| Mar 31, 2022 | 468,125.00 |
| Dec 31, 2021 | 712,768.00 |
| Sep 30, 2021 | 830,859.00 |
| Jun 30, 2021 | 769,247.00 |